Alector, Inc. — Form 8-K summary
Reporting context: The 8-K, filed October 5, 2026, reports agreements entered into on September 30, 2026, and preliminary cash, cash equivalents and marketable securities as of September 30. It is primarily a transaction and liquidity update, not a quarterly earnings report.
Business transactions
- Genentech license: Alector granted Genentech exclusive worldwide rights to develop and commercialize its AL050 engineered GCase enzyme replacement therapy program. Genentech assumes development, regulatory, manufacturing and commercialization responsibilities; Alector will assign certain program-specific patents. Alector retains its Alector Brain Carrier platform and rights to use it outside GCase programs.
- Alector is to receive $100 million upfront and may receive up to an additional $1.17 billion in development, regulatory and commercial milestones, plus tiered royalties ranging from single-digit to double-digit percentages of specified net sales. Milestones and royalties are contingent and are not guaranteed.
- Spur Therapeutics license: Alector exercised an option for a worldwide, royalty-bearing, non-exclusive license to certain engineered-GCase patents. Alector previously paid $500,000 for the option and, following the option exercise and receipt of Genentech’s upfront payment, will pay Spur $15 million. Spur is also entitled to a percentage in the teens of specified milestone and other non-royalty sublicense income, including Genentech milestones, and a portion of royalties Alector receives from sublicensing the Spur patents.
Financial position and key metrics
- Preliminary cash, cash equivalents and marketable securities at September 30, 2026: approximately $138.7 million.
- Pro forma amount after giving effect to the Genentech upfront payment and the Spur payment: approximately $223.7 million (a net increase of $85 million from those payments).
- Management believes the pro forma liquidity will fund operations into 2029. This is an estimate and outlook, not a guarantee.
- The filing provides no clear values for revenue, profit or loss, operating cash flow, margins, or debt.
Changes, outlook and risks
- The agreements monetize and transfer responsibility for the AL050/GCase program while Alector retains its Brain Carrier platform and non-GCase pipeline rights. Alector also assumes payments and revenue-sharing obligations to Spur related to the licensed patents.
- The cash figures are preliminary, unaudited and subject to change after quarter-end close. The company’s independent auditor has not reviewed or performed procedures on them.
- Genentech may terminate its license for convenience on prior written notice; either party may terminate for the other’s insolvency or uncured material breach. Certain termination events may return patents and other assets to Alector, on terms to be agreed. Alector is subject to specified restrictions on certain GCase-related activities for a defined period.
- Under the Spur agreement, either party may terminate for insolvency or uncured material breach; Spur may terminate in certain patent-challenge circumstances, and Alector may terminate for convenience on prior written notice.
- The agreements contain additional terms not fully described in the 8-K. Alector intends to file the agreements in a subsequent periodic report, with certain confidential portions redacted.
Important facts for investors to verify
- Final September 30 cash and securities figures in completed financial statements, and whether the expected payments were received and paid as assumed in the pro forma estimate.
- The definitive Genentech and Spur agreement terms, including redacted provisions, payment timing, milestone conditions, royalty calculations and termination consequences.
- The assumptions supporting management’s estimate that liquidity will fund operations into 2029, including future spending and potential milestone or royalty receipts.
- Any subsequent updates to AL050 development, regulatory and commercial plans under Genentech’s responsibility.